Related Experiment Videos
Targeting head and neck cancer by GM-CSF-mediated gene therapy in vitro
1Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.
Background:
The prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN) has remained poor during the last decades, emphasizing the need for new treatment modalities. Consequently, the objective of our study was to evaluate the feasibility and efficacy of cytokine-mediated gene therapy in SCCHN in vitro.
Materials And Methods/Results:
The SCCHN cell line PCI-1 was transduced by lipofection with a plasmid encoding the human granulocytemacrophage colony-stimulating factor (GM-CSF). Transfection of PCI-1 resulted in the production of significant amounts of GM-CSF as tested by ELISA. Enhanced proliferation of a GM-CSF sensitive cell line, TF-1, after incubation with supernatants of GM-CSF-transduced tumor cells demonstrated the release of biological active GM-CSF from these PCI-1 cells. In addition, GM-CSF-secreting PCI-1 cells enhanced antitumor cytotoxicity of allogeneic peripheral blood mononuclear cells, as tested in 24h-MTT-cytotoxicity assays.
Conclusions:
Our data demonstrate the feasibility and efficacy of GM-CSF-mediated stimulation of the antitumor immune response against SCCHN in vitro and may help to define new strategies in the treatment of this malignancy.
Insights
Gene therapy using granulocyte-macrophage colony-stimulating factor (GM-CSF) shows promise for treating head and neck squamous cell carcinoma. This in vitro study demonstrates GM-CSF gene therapy can stimulate an antitumor immune response against SCCHN.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Prognosis for head and neck squamous cell carcinoma (SCCHN) remains poor, necessitating novel therapeutic approaches.
- Current treatment modalities for SCCHN require enhancement to improve patient outcomes.
Purpose of the Study:
- To assess the feasibility and efficacy of cytokine-mediated gene therapy in SCCHN.
- To investigate the potential of granulocyte-macrophage colony-stimulating factor (GM-CSF) gene therapy for SCCHN.
Main Methods:
- SCCHN cell line PCI-1 was transduced with a plasmid encoding human GM-CSF via lipofection.
- GM-CSF production was quantified using ELISA.
- Biological activity of released GM-CSF was confirmed by enhanced proliferation of TF-1 cells.
- Antitumor cytotoxicity was evaluated using allogeneic peripheral blood mononuclear cells.
Main Results:
- Transfected PCI-1 cells produced significant amounts of GM-CSF.
- Supernatants from GM-CSF-transduced cells promoted proliferation of GM-CSF-sensitive TF-1 cells, confirming active GM-CSF release.
- GM-CSF-secreting PCI-1 cells augmented antitumor immune responses mediated by peripheral blood mononuclear cells.
Conclusions:
- GM-CSF-mediated gene therapy is feasible and effective in stimulating antitumor immunity against SCCHN in vitro.
- These findings support the development of new therapeutic strategies for SCCHN utilizing GM-CSF gene therapy.